Insys therapeutics, inc. (INSY)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Net revenue

82,080

140,693

242,275

-

-

-

-

Net revenue

-

-

-

330,323

219,092

99,289

15,476

Cost of revenue

10,803

20,643

25,393

28,854

22,578

12,665

7,627

Gross profit

71,277

120,050

216,882

301,469

196,514

86,624

7,849

Operating expenses:
Sales and marketing

31,372

48,870

69,651

80,668

58,105

29,194

11,411

Research and development

57,572

62,954

73,913

56,781

33,136

8,499

6,305

General and administrative

39,268

46,487

42,098

62,948

44,283

16,372

8,170

Legal

54,011

21,086

19,994

-

-

-

-

Charges related to litigation award and settlements

16,777

159,684

3,900

10,616

-

0

-

Impairment of intangible assets and goodwill

-

-

-

-

-

-

5,403

Total operating expenses

199,000

339,081

209,556

211,013

135,524

54,065

31,289

Operating loss

-127,723

-219,031

7,326

90,456

60,990

32,559

-23,440

Other income (expense):
Interest expense

-

-

-

-

-

950

2,684

Interest income

1,984

1,881

1,039

502

151

22

-

Other expense, net

-668

-45

59

36

2

-54

1,746

Total other income (expense)

1,316

1,836

1,098

538

153

-982

-938

Loss before income taxes

-126,407

-217,195

8,424

90,994

61,143

-

-

Income (loss) before income taxes

-

-

-

-

-

31,577

-24,378

Income tax expense

-1,900

9,640

834

32,941

25,089

-8,800

0

Net loss

-124,507

-226,835

7,590

58,053

36,054

40,377

-24,378

Unrealized gain (loss) on available-for-sale securities, net of tax of $27 and $0

169

-136

-150

-128

-24

0

-

Total comprehensive loss

-124,338

-226,971

7,440

57,925

36,030

40,377

-

Net loss per common share:
Basic

-1.68

-3.12

0.11

0.81

0.52

0.78

-2.62

Diluted

-1.68

-3.12

0.10

0.77

0.49

0.70

-2.62

Weighted average common shares outstanding
Basic

74,073

72,636

71,639

71,592

68,759

51,839

9,316

Diluted

74,073

72,636

74,166

75,707

73,335

57,469

9,316